Gilead price target raised to $112 from $108 at UBS

UBS raised the firm’s price target on Gilead (GILD) to $112 from $108 and keeps a Neutral rating on the shares. Gilead reported a strong quarter commercially and UBS is optimistic on the launch of Yeztugo for PrEP, the analyst tells investors in a research note. The firm thinks Gilead will continue to show strong demand growth from the core HIV franchise and thinks Yeztugo could be a meaningful source of growth in the medium- to long-term.